Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. uri icon

Overview

authors

  • Assal, Amer
  • Dong, Baoxia
  • Khan, Hina
  • Medavarapu, Ramadevi
  • Shastri, Aditi
  • Pradhan, Kith
  • Friedman, Ellen
  • Mantzaris, Ioannis
  • Janakiram, Murali
  • Battini, Ramakrishna
  • Kornblum, Noah
  • Yu, Yiting
  • Verma, Amit
  • Braunschweig, Ira
  • Derman, Olga

publication date

  • February 17, 2016

Research

keywords

  • Choice Behavior
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Urban Population
  • Vulnerable Populations

Identity

Scopus Document Identifier

  • 84958521129

Digital Object Identifier (DOI)

  • 10.3109/10428194.2016.1142087

PubMed ID

  • 26886689

Additional Document Info

volume

  • 57

issue

  • 10